Dr Reddy’s Laboratories’ consolidated net profit increased marginally by one per cent at Rs. 1,409 crore in the first quarter that ended June 30, 2025, compared to Rs. 1,392 crore in the year-ago period on account of price erosion in North America. Revenue of the Hyderabad-based company, however, increased 11 per cent from Rs. 7,672 crore in Q1 FY25 to Rs. 8,545 crore in Q1 FY26 as per IFRS financials. The marginal growth in profit was primarily driven by price erosion in the North American market — expected in certain key products, such as Lenalidomide — which resulted in an 11 per cent decline in revenue to Rs. 3,400 crore, CFO MV Narasimham told media persons on Wednesday.
Apollo Hospitals and Siemens Healthineers have joined hands for a research collaboration to advance innovation in liver healthcare. The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes — from early detection and risk stratification to monitoring intervention and therapy response, the companies said in a statement.
Biocon Biologics on Wednesday announced the appointment of Deepali Naair as Global Head – Brand & Corporate Communications, effective immediately. Deepali will lead the global brand and corporate communications function, responsible for defining and executing an integrated strategy that spans brand positioning, digital presence, regulatory and statutory communications, financial and corporate reporting, media relations, and employer branding, Biocon Biologics, a subsidiary of Biocon Ltd, said in a statement.
The US health regulator has cited Glenmark Pharmaceuticals for manufacturing lapses, including the failure to establish laboratory controls, at its Pithampur-based plant. In a warning letter, the US Food and Drug Administration (USFDA) also pointed out the company’s failure to follow an adequate written testing programme at the facility to assess stability characteristics of drug products. The USFDA inspected the Pithampur, Madhya Pradesh-based manufacturing plant from February 3-14, 2025.
Natco Pharma on Wednesday said it has offered to acquire nearly 36 per cent stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore in a cash deal. The Hyderabad-based firm said it has submitted a firm intention offer to Adcock Ingram Holdings to acquire the minority shareholders for a cash offer of R75 (approximately USD 4.271) per share. Should the offer be accepted, the company will hold a 35.75 per cent stake in Adcock Ingram, valued at R4 billion (USD 226 million), it stated in a regulatory filing.
Published on July 24, 2025
